Novo Nordisk Wegovy Trial Shows Significant BMI Reduction in Children Aged 6-12
Novo Nordisk has released full results from a late-stage clinical trial demonstrating that its Wegovy injection significantly reduces Body Mass Index (BMI) in children aged 6 to under 12. In the 68-week study, participants receiving Wegovy saw an average BMI reduction of 17.4%, compared to a 2.2% increase in the placebo group. Over 40% of treated children no longer met the clinical criteria for obesity by the end of the trial. The results address a critical unmet medical need, as there are currently no approved medications for treating obesity in children under the age of 12. Novo Nordisk reported that the drug's safety and tolerability profiles were consistent with adult trials, specifically noting no adverse effects on growth or pubertal development. This expansion into younger demographics represents a significant potential market driver for the company's blockbuster weight-loss franchise.

Tickers: $NVO
Topics: childhood obesity clinical trial results Wegovy weight loss drugs
Part of the story Novo Nordisk reports liver improvements with Wegovy in some patients (4 articles)